Pfizer strengthens AI collaboration with XtalPi to accelerate drug discovery
The collaboration aims to enhance the accuracy of physics-based methods with AI models for optimising small molecule medicine discovery and development
The collaboration aims to enhance the accuracy of physics-based methods with AI models for optimising small molecule medicine discovery and development
The approval in China is supported by a robust local clinical development program confirming the drug’s safety, tolerability, and efficacy profile
Eylea 8 mg is the first and only anti-vascular endothelial growth factor (VEGF) treatment in the EU with treatment intervals of up to 6 months for both patients with nAMD and DME
The company's decision to withdraw the MAA was due to the timing of the availability of Chemistry Manufacturing and Controls
WINREVAIR significantly reduced the risk of clinical worsening events in recently diagnosed PAH patients over 70 percent of whom were on double background therapy
The program will start with providing bTrastuzumab to cancer patients facing treatment delays due to budget constraints
The proceeds from the QIP will be utiized for purchase of outstanding optionally convertible debentures
TEMPLE, a Phase 3 multicenter, randomized, double-blind, head-to-head study, evaluated the tolerability, safety and efficacy of atogepant compared to topiramate for the preventive treatment of migraine in adult patients with a history of four or more migraine days per month
Pivotal phase III SUNMO study demonstrated an 11.5 month median progression-free survival - three times longer than R-GemOx
QuantumNexis will serve as the innovative engine for HCTI's recurring revenue business lines
Subscribe To Our Newsletter & Stay Updated